Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + hydromorphone
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intrathecal
01
Overview
A combination medication consisting of bupivacaine, an amide local anesthetic, and hydromorphone, an opioid analgesic. This combination is primarily used in intrathecal (IT) drug delivery systems for managing chronic pain, particularly in patients with failed back surgery syndrome (FBSS) or post-laminectomy syndrome. The combination has shown effectiveness in reducing pain intensity and oral opioid consumption, with bupivacaine helping to attenuate the opioid dose escalation phenomenon commonly observed with intrathecal opioid monotherapy.
- Other names
- Thoracic Epidural AnalgesiaTEA
02
Targets
MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)PTGER1 (Prostaglandin E Receptor 1)
Beyond the preview
Go deeper on bupivacaine + hydromorphone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine + hydromorphone.